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Isoniazid resistance is highly prevalent in Vietnam.We investigated the molecular and epidemiological characteristics and the
association with first-line treatment outcomes of the main isoniazid resistance mutations inMycobacterium tuberculosis in
codon 315 of the katG and in the promoter region of the inhA gene.Mycobacterium tuberculosis strains with phenotypic resis-
tance to isoniazid from consecutively diagnosed smear-positive tuberculosis patients in rural Vietnamwere subjected to Geno-
typeMTBDRplus testing to identify katG and inhAmutations. Treatment failure and relapse were determined by sputum cul-
ture. In total, 227 of 251 isoniazid-resistant strains (90.4%) had detectable mutations: 75.3% in katG codon 315 (katG315) and
28.2% in the inhA promoter region. katG315 mutations were significantly associated with pretreatment resistance to streptomy-
cin, rifampin, and ethambutol but not with the Beijing genotype and predicted both unfavorable treatment outcome (treatment
failure or death) and relapse; inhA promoter regionmutations were only associated with resistance to streptomycin and relapse.
In tuberculosis patients,M. tuberculosis katG315 mutations but not inhAmutations are associated with unfavorable treatment
outcome. inhAmutations do, however, increase the risk of relapse, at least with treatment regimens that contain only isoniazid
and ethambutol in the continuation phase.
With 8.8 million cases notified and 1.4 million deaths in 2010,tuberculosis (TB) remains a major burden to global health
(1). In addition to rifampin, isoniazid is an important drug in
first-line anti-TB treatment (2). Mycobacterium tuberculosis
strains resistant to at least both rifampin and isoniazid are referred
to as multidrug resistant (MDR). Both multidrug resistance and
resistance to isoniazid without concomitant rifampin resistance
are associated with poor response to first-line treatment (3, 4).
Whereas rifampin resistance is usually encoded in a part of the
rpoB gene, the mechanism of resistance to isoniazid is more com-
plex, withmutations conferring resistance in several genomic loci,
such as katG, inhA, ahpC, and, potentially, ndh (5–8). Mutations
in codon 315 of the katG gene (katG315) and in the promoter
region of the inhA gene are by far the most common. katG315
mutations occur in 50 to 95% of isoniazid-resistant strains (6, 9,
10), whereas 20 to 42% of such strains have mutations in the
promoter region of the inhA gene (6, 10, 11), depending on the
geographic region studied.
Isoniazid is activated by the enzyme catalase peroxidase, en-
coded by katG (12). katG mutations lead to high-level isoniazid
resistance (to 1.0 g/ml in 7H10 agar) (13). The inhA gene
encodes an enoyl acyl carrier protein reductase involved in fatty
acid synthesis. These fatty acids are the target of the active deriv-
ative of isoniazid. inhAmutations usually lead to low-level isoni-
azid resistance (resistant to 0.2 g/ml in 7H10 agar) (13, 14).
katG315 mutations have been shown to be associated with
MDR-TB and TB transmission (15, 16). Such mutations were
more frequent among patients infected with Beijing genotype
strains (17, 18), which are common in East Asia, including Viet-
nam (19, 20), and related to drug resistance (20, 21), as well as to
relapse in various areas (22, 23). These differences in isoniazid
resistance-conferringmutationsmay also be related to other char-
acteristics of M. tuberculosis strains, as well as to treatment out-
comes. There are, however, very few studies on the mutations
underlying resistance to anti-TB drugs and treatment outcome.
We therefore studied the epidemiology of katG and inhA muta-
tions in M. tuberculosis isolates and the clinical characteristics of
the respective patients inVietnam,where the prevalence of smear-
positive TB was 197/100,000 in 2006-2007 (24) and resistance to
isoniazid is common (16 to 25% in new patients) (25). For this we
assessed M. tuberculosis genotype and TB treatment outcomes in
association with katG and inhA mutations in a prospective, pop-
ulation-based study.
MATERIALS AND METHODS
Study subjects.The study area consisted of three adjacent rural districts in
Tiengiang Province in the Mekong River Delta in Southern Vietnam.
Details of the study have been described elsewhere (26).
From 1 July 2005 to 30 June 2007, all patients aged15 years, resident
in the study area and registered for treatment of smear-positive pulmo-
nary TB, were eligible for inclusion after provision of written informed
consent. Excluded were patients who received treatment for more than 2
weeks before registration. Ethical clearance for the study was obtained
from the ethical health committee of the Ho Chi Minh City Council.
According to the guidelines of the VietnamNational TB Control Pro-
gram (27) patients with no history of treatmentwith anti-TB drugs for1
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month (i.e., new TB cases) were treated with 2 months of daily strepto-
mycin (S), isoniazid (H), rifampin (R), andpyrazinamide (Z), followed by
daily ethambutol (E) and isoniazid for 6 months (2SHRZ/6EH). Previ-
ously treated patients were given all five drugs (SHRZE) daily for 2
months and then four drugs (HRZE) for one more month, followed by
RHE 3 days per week for 5 months. All doses were given under directly
observed treatment as long as patients were given rifampin, irrespective of
treatment phase or regimen. Drug susceptibility testing was done later,
and results were not used to modify treatment regimens. Treatment ad-
herence was confirmed from the treatment cards kept at the district tu-
berculosis unit (DTU).
Study design. The purpose of the present study was to quantify pos-
sible associations between isoniazid resistance-conferring mutations in
the M. tuberculosis strain isolated before treatment and M. tuberculosis
genotype and patient characteristics among all TB patients, and between
pretreatment isoniazid resistance-conferring mutations and treatment
outcomes (treatment failure and relapse) among new TB cases. New TB
patients were followed up during standard first-line treatment with spu-
tum smear microscopy at months 3, 5, and 8 and with sputum culture at
the end of treatment (after 8 months, or after 5 months if the month 5
smear was positive). Participants whose sputum smear and culture were
negative for M. tuberculosis at the end of treatment were visited by study
staff twice thereafter, at around 9 and 18 months after treatment comple-
tion, or later if not encountered. In addition, data were collected during
this period on study participants reporting with TB symptoms at any of
the study clinics. Participants who had any complaints suggesting recur-
rent TB during these visits, or when they themselves consulted a partici-
pating clinic, provided two sputum specimens for smear and culture. The
data were also collected on any intermediate TB treatment elsewhere, and
on causes of death among the study patients based on clinic reports, death
certificates and interviews with family members.
Laboratory methods. Sputum specimens were kept refrigerated and
transported to PhamNgoc ThachHospital inHoChiMinhCity within 72
h after collection. They were decontaminated and liquefied with 1% N-
acetylcystine–2% NaOH, inoculated on modified Ogawa medium, and
incubated at 37°C. Cultures were examined for growth after 1, 2, 4, 6, and
8 weeks of incubation. Cultures with no growth after 8 weeks were re-
ported as negative.M. tuberculosis was identified using the niacin and the
nitrate tests.
Drug susceptibility testing (DST)was performed using the proportion
method on Löwenstein-Jensen (LJ) medium (28). Criteria for drug resis-
tance were 1% of the CFU grown at 28 or 42 days compared to the
drug-free control medium at the following drug concentrations: isonia-
zid, 0.2g/ml; rifampin, 40g/ml; streptomycin, 4g/ml; and ethambu-
tol, 2 g/ml (28). All isoniazid-resistant M. tuberculosis strains that were
isolated were subjected to testing by GenoType MTBDRplus that com-
bines detection ofM. tuberculosis complex with detection of mutations in
the 81-bp hot spot region of rpoB, at codon 315 of the katG gene and in the
inhA promoter region (15). All baseline and follow-up isolates from pa-
tients with positive follow-up M. tuberculosis cultures were subjected to
molecular typing by spoligo and variable number of tandem repeats
(VNTR) typing. Bacterial DNAwas extracted frompositive cultures using
an earlier describedmethod (29). Spoligotypingwas performed according
to the internationally standardized method (30), and VNTR typing was
done using15 loci (31).
Definitions. Previously treated patients were those who received 1
month or more of anti-TB drugs in the past. Cure was defined as a nega-
tive sputum smear examination and culture in the lastmonth of treatment
and on at least one previous occasion, and treatment failurewas defined as
any positive sputum smear or culture at 5 months or later during treat-
ment. Treatment completion was defined as having completed treatment
without meeting the criteria for being classified as cure or failure.
Recurrent TB was defined as any case of positive smear and/or culture
during the follow-up period among the cured patients (32). We defined a
case of recurrent TB as relapse if the initial and follow-upM. tuberculosis
isolates had identical spoligotypes and VNTR patterns, or if the VNTR
patterns differed by1 locus, and as reinfection if otherwise (31). Unfa-
vorable treatment outcome was referred to as treatment failure or death
and related to the treatment period only.
Genotypes were based on spoligotyping. The Beijing genotype was
defined as any isolate without direct-repeat spacers 1 to 34 and the pres-
ence of at least three of the spacers from 35 to 43 (33). Other genotypes,
including the East African-Indian (EAI) genotype that is predominant in
Vietnam, were defined as described by Brudey et al. (34).
Data analysis. Data were double entered in Epi-Info (version 6.04;
Centers for Disease Control and Prevention, Atlanta, GA); discrepancies
were corrected based on the raw data. Analyses were performed in Stata
(version 10SE; Stata Corp., College Station, TX).
For comparison of categorical variables we used the chi-squared and
two-sided Fisher exact tests as appropriate. Associations of katG315 or
inhAmutations with explanatory variables before start of treatment were
expressed as odds ratios (ORs); confounding effects were investigated by
multivariable logistic regression modeling. In the analysis of treatment
failure,mutations in katG and inhAwere assessed bymultivariable logistic
regression as explanatory variables, along with covariates that showed
confounding effects, potentially including age, sex, residence, resistance
to other drugs, theM. tuberculosis genotype, pretreatment smear grading
and the extent of chest X-ray abnormalities, and treatment adherence.
Only variables that showed confounding effects for the association be-
tween resistance mutations and the outcome were retained in the final
model. Since patients who died during treatment may reflect treatment
failures, we repeated this analysis taking failure or death as unfavorable
treatment outcome. For the association with relapse, we did a similar
analysis using multivariable Cox’ proportional hazardmodeling. P values
for contribution tomultivariatemodels, including interaction,were based
on the likelihood ratio test. All tests were done at the 5% significance level.
RESULTS
After excluding 151 patients (Fig. 1), pretreatment datawere avail-
able for analysis for 1,213 (88.9%) of 1,364 registered patients. Of
these, 924weremale (76.2%); themean agewas 50 years (standard
deviation [SD]  18.3; range, 15 to 102). There were 1,102
(90.9%) new patients and 111 (9.1%) patients previously treated
for TB.
Of 1,213M. tuberculosis pretreatment isolates, 69 (5.7%) were
monoresistant to isoniazid, 146 (12.4%) were monoresistant to
streptomycin, 128 (10.6%) were resistant to isoniazid and strep-
tomycin, and 47 (3.9%) were multidrug resistant (see Table S1 in
the supplemental material). Monoresistance to isoniazid was
more frequent amongpreviously treated patients than amongnew
TB patients (12.6% versus 5.0%, P  0.05), whereas the propor-
tion of other monoresistance patterns did not significantly differ
between previously treated and new patients.
Isoniazid resistance-conferring mutations. Of the 251
(20.7%) phenotypically isoniazid-resistantM. tuberculosis strains,
227 (90.4%) exhibited mutations by GenoType MTBDRplus test-
ing; 171 (75.3%) hadmutations or no reaction onwild-type (WT)
probes in katG315, including 167 (97.7%) with katG S315T1 mu-
tations. Sixty-four (28.2%) had mutations in the inhA promoter
region, including 61 (95.3%) involving inhA C15T mutations.
Only 8 of 227 (3.5%) strains with a katG315 mutation had an ad-
ditional mutation in the inhA promoter region (Table 1).
Characteristics for katG315 mutations. There were no signifi-
cant associations between the probability of having a strain with a
katG315 mutation and the patient’s district, type of residence, age
or presence of mutations in the inhA promoter region. However,
katG315 mutations were significantly more frequent among
women (odds ratio [OR] 1.4), among patients previously treated
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for TB (OR 5.3), among strains that were resistant to rifampin
(OR 27.7), streptomycin (OR 16.9), or ethambutol (OR 62.1), and
among strains that belonged to the Beijing genotype (OR 3.2).
In a multivariable model katG315 mutations remained associ-
ated (adjusted OR [ORadj]; 95% confidence interval [CI]) with
previous TB treatment (2.6; 1.4 to 4.8), resistance to rifampin (4.5;
1.8 to 11.1), ethambutol (12.0; 2.7 to 54.4) or streptomycin (15.0;
9.4 to 23.9), as well as with female sex (1.9; 1.2 to 3.0), but not with
the Beijing genotype (1.3; 0.8 to 2.2) or EAI genotype (1.7; 0.9 to
3.0) compared to all other genotypes together (Table 2). When
leaving resistance to other drugs than isoniazid out of the model,
the Beijing genotype (2.6; 1.7 to 4.1) but not the EAI genotype was
associated with katG315 mutation.When adding resistance to only
one of the three other drugs to themodel, the Beijing genotypewas
still significantly associated with katG315 mutations after adjust-
ment for rifampin (2.2; 1.4 to 3.4) or ethambutol resistance (2.5;
1.6 to 4.0), whereas this association disappeared after adjustment
for streptomycin resistance (1.5; 0.9 to 2.5).
Characteristics for inhA promoter regionmutations. In uni-
variate analysis, inhAmutations were associated with previous TB
treatment (OR 2.7), with resistance to rifampin (OR 3.2), strepto-
mycin (OR 3.1), or ethambutol (OR 4.0) and with living in one of
the districts (Caibe, OR 2.4), but not with sex, age, residence, or
genotype. In multivariate analysis also including resistance to
other drugs, inhA mutations remained significantly associated
with resistance to streptomycin (ORadj 4.4; 95% CI  2.4 to 8.1)
and previous TB treatment (ORadj 2.5; 95% CI 1.2 to 5.4), and
near-significantly associated with the Caibe district (ORadj 2.1;
P  0.066) but not with resistance to rifampin or ethambutol
(Table 3). There was significant interaction between previous TB
treatment and streptomycin resistance: inhAmutations were sig-
nificantly associated with streptomycin resistance among new TB
patients (ORadj 6.5, P 0.001) but not among previously treated
patients (ORadj 0.36, P 0.05).
Predictors of treatment failure. Of 1,102 new TB patients,
51were excluded due to loss of data (30), reinfection (7), default-
ing (9), transfer-out (3), and changed treatment regimen because
of side effects (2). Furthermore, we excluded 41 patients who died
during treatment, leaving 1,010 new patients for this analysis (Fig.
1). Of these, 21 (2.1%) had a treatment failure (Table 4).
In univariate analysis, the risk of treatment failure was signifi-
cantly increased for isoniazid-resistant strains having at least a
katG315 mutation (OR 13.6; 95%CI 5.3 to 35.4) but not for isoni-
azid-resistant strains having inhAmutations only (OR2.9; 95%CI
0.3 to 14.0) or no mutations (OR 6.9; 95% CI 0.8 to 59.6). After
multivariable adjustment for district and resistance to rifampin,
FIG 1 Schematic presentation of enrollment of the study population. TB, tuberculosis.
TABLE 1 Results of isoniazid resistance mutations detected by
MTBDRplus test among 227 TB patients with phenotypic resistance to
isoniazid in Vietnam
Mutation(s) Frequency
katG inhA
No. of
patients % Total
WT (315) absent 171 75.3
MUT1 (S315T1) 167 73.6
MUT2 (S315T2) 0 0
WT (15/16) absent 56 24.7
WT (8) absent 5 2.2
MUT1 (C15T) 61 26.9
MUT2 (A16G) 0 0
MUT3A (T8C) 0 0
MUT3B (T8A) 3 1.3
MUT1 (S315T1) MUT1 (C15T) 8 3.5
Huyen et al.
3622 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://aac.asm
.org/
D
ow
nloaded from
 
streptomycin, or ethambutol, the association between katG315muta-
tions and treatment failure (ORadj; 95%CI)was no longer significant
(3.2; 0.8 to 12.8;Wald test, P 0.102). Similarly, neither inhAmuta-
tions only (1.0; 0.1 to 10.1) nor isoniazid resistance without muta-
tions detectable by the MTBDRplus assay (1.8; 0.1 to 24.1) showed
significant associationwith treatment failure (Table 4). Therewas no
significant difference in failure between patients with katG315 and
patients with inhA mutated strains. Isoniazid resistance mutations
showed no association with treatment adherence, pretreatment
smear grade, and the extent of pretreatment abnormalities, andnone
of these variables confounded the observed associations between re-
sistance mutation and treatment failure.
When the 41 patients who had died during treatment were
included in the analysis and failure or death (62 of 1,051 patients;
5.9%) was combined as unfavorable treatment outcome, its risk
was significantly increased for isoniazid-resistant strains having at
least a katG315 mutation (OR 3.7; 95% CI  2.0 to 6.7) or no
mutations detectable by theMTBDRplus assay (OR 3.7; 95%CI
1.1 to 13.3) but not for inhA mutations only (OR 1.0; 95% CI 
0.2 to 4.4). In a multivariate model adjusting for covariates that
appeared to confound this association (resistance to rifampin or
resistance to streptomycin) unfavorable treatment outcome re-
mained significantly associated with the katG315 mutations (OR
adj
3.0; 95% CI  1.4 to 6.8; Wald test P  0.007) but not with no
TABLE 2 Univariable and multivariable associations with patient characteristics, genotype, and anti-TB drug resistance for katG codon 315
mutations at the start of treatment (baseline)
Characteristic or parameter
No. of
patients
katGmutations OR (95% CI)a
PNo. % Crude Adjusted
Total no. of subjects 1,213
Sex 0.009
Male 924 120 13 1 1
Female 289 51 17.7 1.4 (1.0–2.05) 1.9 (1.2–3.0)
Age (yrs) 0.349
25 119 16 13.5 1 1
25 to 49 528 79 15 1.1 (0.6–2.0) 1.7 (0.8–3.7)
50 566 76 13.4 1.0 (0.6–1.8) 1.7 (0.8–3.7)
History of TB 0.002
New 1,102 126 11.4 1 1
Previously treated 111 45 40.5 5.3 (3.4–8.2) 2.6 (1.4–4.8)
District
Cailay 440 60 13.6 1
Caibe 418 57 13.6 1.0 (0.7–1.5)
Chauthanh 355 54 15.2 1.1 (0.8–1.7)
Residence
On waterway 457 67 14.7 1
On provincial road 624 91 14.6 1.0 (0.7–1.4)
On national road 132 13 9.9 0.6 (0.3–1.2)
Genotype family 0.203
East African-Indian 461 40 8.7 0.9 (0.6–1.5) 1.7 (0.9–3.0)
Beijing 407 98 24.1 3.0 (2.0–4.6) 1.3 (0.8–2.2)
Other 345 33 9.6 1 1
Rifampin resistance 0.001
No 1,163 132 11.4 1 1
Yes 50 39 78 27.7 (13.1–58.6) 4.5 (1.8–11.1)
Streptomycin resistance 0.001
No 889 36 4.1 1 1
Yes 324 135 41.7 16.9 (10.7–26.7) 15.0 (9.4–23.9)
Ethambutol resistance 0.001
No 1,184 145 12.3 1 1
Yes 29 26 89.7 62.1 (17.2–224.4) 12.0 (2.7–54.4)
InhA mutation 0.001
No 1149 163 14.2 1 1
Yes 64 8 12.5 0.9 (0.4–1.9) 0.2 (0.1–0.5)
a “Adjusted” means adjusted for all other variables in the model. CI, confidence interval; OR, odds ratio.
Isoniazid Resistance Mutations
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detectable mutations (ORadj 3.4; 95%CI 0.9 to 13.4; P 0.081)
(Table 4).
Predictors of relapse.For this analysis, we included all 984new
patients who were smear and culture negative at the end of treat-
ment and available for follow-up (Fig. 1).We observed 31 cases of
recurrent TB, of which 9 were classified as reinfections and 22
(2.2%) were classified as relapse. There were no relapses among
the 17 participants with isoniazid-resistant isolates that did not
display any mutation in the MTBDRplus assay. The three strains
that displayed both a katG315 and an inhAmutationwere included
in the katG315 mutation category.
In univariate analysis, both katG315 and inhA mutations were
strongly associatedwith relapse; hazard ratios (HR)were 6.7 (95%
CI 2.6 to 16.9) and 8.3 (95%CI 2.6 to 26.4), respectively (Fig.
2). Relapse was also significantly more frequent among partici-
pants harboring strains that were of the Beijing genotype (HR 6.2)
or streptomycin resistant (HR 4.0) and among those with
MDR-TB (HR 7.4).
After multivariable adjustment for genotype and resistance to
streptomycin or rifampin, relapse remained strongly associated
with katG315 mutations (HR
adj 4.3; 95% CI  1.4 to 13.6, P 
0.013) and inhAmutations (HRadj 8.7; 95% CI 2.5 to 30.0, P
0.001) compared against isoniazid-susceptible strains (Table 5).
The relapse rate did not differ significantly between strains with
TABLE 3 Univariable and multivariable associations with patient characteristics, genotype, and anti-TB drug resistance for the inhA promoter
region mutations at the start of treatment (baseline)
Characteristic or parameter
No. of
patients
inhAmutations OR (95% CI)a
PNo. % Crude Adjusted
Total 1,213
Sex 0.184
Male 924 46 5 1 1
Female 289 18 6.2 1.3 (0.7–2.2) 1.5 (0.8–2.7)
Age group (yrs) 0.453
25 119 4 3.4 1 1
25 to 49 528 30 5.7 1.7 (0.6–5.0) 1.9 (0.6–5.9)
50 566 30 5.3 1.6 (0.6–4.7) 1.7 (0.6–5.1)
History of TB 0.025
New 1,102 51 4.6 1 1
Previously treated 111 12 11.7 2.7 (1.4–5.2) 2.5 (1.2–5.4)
District 0.066
Cailay 440 14 3.2 1 1
Caibe 418 31 7.4 2.4 (1.3–4.7) 2.1 (1.1–4.1)
Chauthanh 355 19 3.4 1.7 (0.9–3.5) 1.3 (0.6–2.8)
Residence
On waterway 457 25 5.5 1
On provincial road 624 32 5.1 0.9 (0.6–1.6)
On national road 132 7 5.3 1.0 (0.4–2.3)
Genotype family 0.276
East African-Indian 461 21 4.6 0.7 (0.4–1.4) 1.0 (0.5–2.0)
Beijing 407 22 5.4 0.9 (0.5–1.6) 0.6 (0.3–1.2)
Other 345 21 6.1 1 1
Rifampin resistance 0.496
No 1,163 57 4.9 1 1
Yes 50 7 14 3.2 (1.4–7.4) 1.6 (0.5–5.4)
Streptomycin resistance 0.001
No 889 31 3.5 1 1
Yes 324 33 10.2 3.1 (1.9–5.2) 4.4 (2.4–8.1)
Ethambutol resistance 0.122
No 1,184 59 5 1 1
Yes 29 5 17.2 4.0 (1.5–10.8) 3.3 (0.8–14.3)
katGmutation 0.001
No 1,042 56 5.4 1 1
Yes 171 8 4.7 0.9 (0.4–1.8) 0.2 (0.1–0.6)
a “Adjusted” means adjusted for all other variables in the model.
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katG315mutations, and strains with inhAmutations.We found no
significant interactions.
DISCUSSION
In this population-based study conducted in Vietnam, katG315
mutations occurred in 75% of the isoniazid-resistant strains and
weremore often found in strains resistant to rifampin, streptomy-
cin, or ethambutol. In contrast, the inhA promoter region muta-
tionswere less frequent among isoniazid-resistant strains and only
associated with streptomycin resistance. Follow-up of new TB pa-
tients on standard first-line treatment showed that katG315 and
inhA promoter region mutations were both strongly associated
with relapse. katG315 mutations showed a 3-fold but nonsignifi-
cant association with treatment failure, while inhA promoter re-
gion mutations showed no such association at all. Unfavorable
treatment outcome was, however, significantly associated with
katG315 mutations, as previously reported by Tolani et al. (35).
This was expected because these mutations confer high-level iso-
niazid resistance (13). The independent association between
katG315 and failure was nonsignificant, probably because of small
numbers, which is supported by the finding that the association
was of similarmagnitude but now significant when treatment fail-
ure and death were combined.We found no associations between
katG315 or inhAmutations and the Beijing genotype.
A strong association between katG315 and inhAmutations and
relapse may be caused by the 8-month 2SHRZ/6EH regimen used
for new TB patients in Vietnam. This means that not only with
high-level but also with low-level isoniazid resistance the supple-
mentation of isoniazid with only ethambutol in the continuation
phase of treatment is not effective in sterilizing M. tuberculosis.
TABLE 4Multivariable associations for treatment failure or treatment failure and death during treatment combined
Resistance
Failurea Failure or deathb
Total No. %
Adjusted OR
(95% CI) P Total No. %
Adjusted OR
(95% CI) P
Isoniazid resistance 0.370 0.046
Susceptible 834 7 0.8 1 866 39 4.5 1
Any katGmutation 116 12 10.3 3.2 (0.8–12.8) 0.102 122 18 14.8 3.0 (1.4–6.8) 0.007
InhA mutations only 42 1 2.4 1.0 (0.1–10.0) 0.974 43 2 4.7 1 (0.2–4.5) 0.994
No mutations 18 1 5.6 1.8 (0.1–24.1) 0.657 20 3 15.0 3.4 (0.9–13.4) 0.081
Rifampin resistance 0.001 0.001
No 986 12 1.2 1 1027 53 5.2 1
Yes 24 9 37.5 7.6 (1.7–34.1) 24 9 37.5 6.3 (2.3–17.1)
Streptomycin resistance 0.191 0.348
No 760 7 0.9 1 794 41 5.2 1
Yes 250 14 5.6 2.3 (0.7–8.2) 257 21 8.2 0.7 (0.3–1.5)
Ethambutol resistance 0.056
No 997 15 1.5 1 1038 56 5.4 –
Yes 13 6 46.2 5.9 (1.0–32.3) 13 6 46.2
a The model for the OR and P values includes the following covariates: district, isoniazid resistance, rifampin resistance, streptomycin resistance, and ethambutol resistance.
b The model for the OR and P values includes the following covariates: isoniazid resistance, rifampin resistance, and streptomycin resistance.
FIG 2 Inverted survival curve for tuberculosis relapse cases among 984 pa-
tients after first line TB treatment, isoniazid resistance-conferring mutations.
Log-rank test,P 0.001. Solid black line, cases due to katG codon 315mutated
strains. Interrupted black line, cases due to inhA promoter region-only mu-
tated strains. Gray line, cases due to isoniazid-susceptible strains. y axis, pro-
portion of relapse cases. INH, isoniazid.
TABLE 5Multivariable associations for relapse in 967 new TB patientsa
Resistance
No. of
relapses
Incidence per 100
person-years of
follow-up
Adjusted
hazard
ratio 95% CI P
Total 22
Isoniazid resistance 0.004
Susceptible 10 0.78 1
Any katGmutations 8 5.14 4.3 1.4–13.6 0.013
inhAmutations only 4 6.34 8.7 2.5–30 0.001
Rifampin resistance 2 9.21 1.2 0.3–5.7 0.821
Streptomycin
resistance
12 3.5 1.1 0.4–3.1 0.900
Genotype 0.001
Beijing 3.46 5.1 1.9–14
Non-Beijing 0.58 1
a Variables in the model: isoniazid resistance mutations, Beijing genotype, streptomycin
resistance, and rifampin resistance. A total of 17 patients with isoniazid-resistant strains
for which no mutation was found were excluded from the analysis.
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Interestingly, the association between isoniazid resistance and re-
lapse was most pronounced for inhA mutations. Since the cata-
lase-peroxidase release is a component of the bacterial oxyR re-
sponse, this helps the bacteria to survive insidemacrophages (36).
Hence, the probability of survival of bacteria with an inhAmuta-
tion inside macrophages is higher than for the katG315 mutant
strains because they still have full catalase-peroxidase expression.
Whether the increased risk of relapse, in particular for inhA mu-
tations, also exists with the World Health Organization (WHO)-
recommended 6-month regimen (2RHEZ/4RH) remains to be
studied.
In the univariate analysis katG315 mutations were strongly as-
sociated with the Beijing genotype. Although in accordance with
previous studies (9, 17, 18), this association completely disap-
peared after adjustment for streptomycin resistance. In our study
47% of the Beijing strains were resistant to streptomycin of which
48% also had katG315 mutations, suggesting that in the Beijing
strains streptomycin resistance and katG315 mutations are often
present simultaneously. This correlation is not unexpected; strep-
tomycin resistance was also associated with the Beijing genotype,
MDR-TB and increased transmission in the same study area (37).
The association between streptomycin resistance and high-level
isoniazid resistance and MDR, especially among Beijing strains,
needs further study. It might be related to a specific combination
of low-fitness cost mutations conferring these resistances and the
strain’s genetic background. In addition, yet-unknown compen-
satory mutations may contribute to the strain’s fitness.
Our findings also have consequences for the choice of the stan-
dard first-line regimen inVietnam. In linewithWHOrecommen-
dations, the 8-month regimen for the treatment of new TB pa-
tients should be replaced by the 6-month regimen, including
rifampin in the continuation phase.
There were limitations to our study.We only tested isolates for
mutations that showed phenotypic resistance to isoniazid and
may have missed genotypically isoniazid-resistant isolates. How-
ever, drug susceptibility testing was done by an internationally
recognized reference laboratory that has consistently shown high
concordance rates in proficiency testing therefore this risk is small.
We did not determine theMICs of isoniazid for theM. tuberculosis
isolates. We also did not use other genotyping methods to assess
the type of mutations conferring isoniazid resistance other than
those included in theMTBDRplus test. However, theMTBDRplus
test covers 90% of the isoniazid mutations in M. tuberculosis
isolates in Vietnam, as shown previously (15). HIV testing was not
routinely performed for all patients. However, the HIV infection
prevalence in Vietnam is estimated to be 0.4% of the adult popu-
lation, with substantially lower prevalence in rural provinces than
in major cities. We collected no data on clinical characteristics
known to predict treatment failure or relapse, such as the presence
of comorbidities or cavities on the chest X-ray. Since it is unlikely
that these would be associated with specific isoniazid resistance-
conferring mutations before treatment, we do not expect that this
resulted in uncontrolled confounding of the observed associa-
tions.
In conclusion, isoniazid resistance was most frequently due to
mutations in the katG315 gene, and these mutations were associ-
ated with multidrug and polydrug resistance, whereas inhA mu-
tations were less frequent and were only associated with strepto-
mycin resistance. Both katG315 and inhAmutations increased the
risk of relapse. Our results also suggest that in Vietnam the
8-month regimen should be discontinued and be replaced by
the WHO-recommended 6-month regimen for the treatment of
new TB patients.
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